Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
25 Aug 2022
Historique:
entrez: 2 9 2022
pubmed: 3 9 2022
medline: 3 9 2022
Statut: epublish

Résumé

The Omicron variant of SARS-CoV-2 evades neutralization by most serum antibodies elicited by two doses of mRNA vaccines, but a third dose of the same vaccine increases anti-Omicron neutralizing antibodies. By combining computational modeling with data from vaccinated humans we reveal mechanisms underlying this observation. After the first dose, limited antigen availability in germinal centers results in a response dominated by B cells with high germline affinities for immunodominant epitopes that are significantly mutated in an Omicron-like variant. After the second dose, expansion of these memory cells and differentiation into plasma cells shape antibody responses that are thus ineffective for such variants. However, in secondary germinal centers, pre-existing higher affinity antibodies mediate enhanced antigen presentation and they can also partially mask dominant epitopes. These effects generate memory B cells that target subdominant epitopes that are less mutated in Omicron. The third dose expands these cells and boosts anti-variant neutralizing antibodies.

Identifiants

pubmed: 36052368
doi: 10.1101/2022.08.24.505127
pmc: PMC9435403
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : U19 AI057229
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

Science. 2016 Mar 4;351(6277):1048-54
pubmed: 26912368
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D195-8
pubmed: 16381844
Immunity. 2017 Jun 20;46(6):1073-1088.e6
pubmed: 28636956
Cell. 2015 Feb 12;160(4):785-797
pubmed: 25662010
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Immunity. 2019 Oct 15;51(4):735-749.e8
pubmed: 31563464
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Curr Opin Immunol. 2018 Aug;53:209-216
pubmed: 30190230
Cold Spring Harb Perspect Med. 2020 Aug 3;10(8):
pubmed: 31871236
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Nature. 2007 Mar 1;446(7131):83-7
pubmed: 17268470
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
J Virol. 2004 Oct;78(19):10582-7
pubmed: 15367625
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145
pubmed: 35085224
Sci Transl Med. 2021 Nov 24;13(621):eabk1533
pubmed: 34818054
Front Immunol. 2017 Mar 06;8:238
pubmed: 28321225
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Immunity. 1998 Jun;8(6):751-9
pubmed: 9655489
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6639-E6648
pubmed: 27702895
Science. 2006 May 5;312(5774):738-41
pubmed: 16675699
Cell. 2020 Aug 20;182(4):843-854.e12
pubmed: 32673567
Immunol Rev. 2019 Mar;288(1):49-63
pubmed: 30874353
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Sci Immunol. 2022 Apr 22;7(70):eabn8590
pubmed: 35113654
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
EClinicalMedicine. 2021 Aug;38:101018
pubmed: 34278286
Trends Immunol. 2019 Jan;40(1):35-48
pubmed: 30502023
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
J Exp Med. 2013 Mar 11;210(3):457-64
pubmed: 23420879
Nat Med. 2020 Mar;26(3):430-440
pubmed: 32066977
Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13474-13479
pubmed: 31213541
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Cell Res. 2022 Jul;32(7):691-694
pubmed: 35672388
Cell. 2020 Jan 9;180(1):92-106.e11
pubmed: 31866068
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
J Control Release. 2015 Nov 10;217:345-51
pubmed: 26264835
J Exp Med. 1991 May 1;173(5):1165-75
pubmed: 1902502
EBioMedicine. 2022 Jun;80:104066
pubmed: 35605428
Nat Commun. 2018 Aug 22;9(1):3372
pubmed: 30135429
N Engl J Med. 2022 Apr 7;386(14):1377-1380
pubmed: 35297591
Cell Syst. 2020 Dec 16;11(6):573-588.e9
pubmed: 33031741
J Immunol. 2017 Aug 15;199(4):1301-1307
pubmed: 28687657
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
N Engl J Med. 2022 Mar 3;386(9):894-896
pubmed: 35081296
Cell. 2020 Nov 25;183(5):1298-1311.e11
pubmed: 33125897
Sci Transl Med. 2021 Jun 30;13(600):
pubmed: 34103407
J Exp Med. 2021 Feb 1;218(2):
pubmed: 33355623
Cell. 2015 Oct 22;163(3):545-8
pubmed: 26496601
PLoS Biol. 2005 Jun;3(6):e150
pubmed: 15857154
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
J Exp Med. 2011 Jun 6;208(6):1243-52
pubmed: 21576382
Sci Rep. 2018 Oct 16;8(1):15292
pubmed: 30327481
Immunity. 2022 Aug 4;:
pubmed: 35987201
Science. 2013 Sep 13;341(6151):1199-204
pubmed: 24031012
Curr Top Microbiol Immunol. 2006;299:141-70
pubmed: 16568898
Sci Immunol. 2021 Dec 10;6(66):eabl5842
pubmed: 34648356
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
EBioMedicine. 2022 Jan;75:103796
pubmed: 34971970
Immunity. 2016 Mar 15;44(3):542-552
pubmed: 26948373
Science. 2017 Oct 13;358(6360):
pubmed: 28935768
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Proc Natl Acad Sci U S A. 2022 Sep 13;119(37):e2205598119
pubmed: 36006981
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
Cell Host Microbe. 2020 Oct 7;28(4):572-585.e7
pubmed: 32697938
Immunity. 2002 Jan;16(1):123-34
pubmed: 11825571
Cell. 2016 Sep 8;166(6):1445-1458.e12
pubmed: 27610569
Immunity. 2018 Feb 20;48(2):313-326.e5
pubmed: 29396161
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Cell. 2019 May 16;177(5):1153-1171.e28
pubmed: 31080066
Biomaterials. 2021 Aug;275:120868
pubmed: 34091299
Cell. 2010 Nov 12;143(4):592-605
pubmed: 21074050
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
PLoS Comput Biol. 2010 Jun 03;6(6):e1000800
pubmed: 20532164

Auteurs

Leerang Yang (L)

Departments of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.

Matthew Van Beek (M)

Departments of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.

Zijun Wang (Z)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.

Frauke Muecksch (F)

Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.

Marie Canis (M)

Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.

Theodora Hatziioannou (T)

Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.

Paul D Bieniasz (PD)

Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Howard Hughes Medical Institute.

Michel C Nussenzweig (MC)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Howard Hughes Medical Institute.

Arup K Chakraborty (AK)

Departments of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139.
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139.
Institute for Medical Engineering & Science, Massachusetts Institute of Technology; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139.

Classifications MeSH